ImmunoGen, Inc. Announces Webcasts of Presentations at Upcoming Investor Conferences

WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced that the following presentations by Company management at upcoming investor conferences will be webcast:

• Leerink Partners 5th Annual Global Healthcare Conference2:40 pm ET, February 10

• RBC Capital Markets Global Healthcare Conference11:30 am ET, February 23
• Cowen and Company 36th Annual Health Care Conference9:20 am ET, March 8

The webcasts will be accessible live through the “Investors” section of the Company’s website, www.immunogen.com; a replay will be available at the same location for approximately a week.

About ImmunoGen, Inc.

ImmunoGen is a clinical-stage biotechnology company that develops targeted anticancer therapeutics using its proprietary ADC technology. The Company's lead product candidate, mirvetuximab soravtansine, is a potential treatment for folate receptor α-positive ovarian cancer and other solid tumors. A number of major healthcare companies have licensed limited rights to use ImmunoGen's ADC technology to develop anticancer therapies; it is used in Roche's marketed product, Kadcyla®. More information about the Company can be found at www.immunogen.com.

Kadcyla® is a registered trademark of Genentech, a member of the Roche Group.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160203005095/en/

ImmunoGen, Inc.
Carol Hausner, 781-895-0600
[email protected]

Source: ImmunoGen, Inc.

You May Also Be Interested In

• YFORE Debuts ODMS In-Cabin Sensing System to Enhance Cockpit Safety
• 360in360 Living Memories Adds Audiobook and Voice-Preservation Capability
• Crypto Market Rotation Watch: VOIDTRACE AI Targets the Data Gap Between Major Assets, AI Tokens and Presales